Climb Bio Inc CLYM

$10.06 +0.49 (5.12%)

Valuation

Market cap
585,273,000
Revenue TTM
$0
Net income TTM
$-59,850,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
492,077
Avg volume
1,476,450
Day's range
$9.25 – $10.04
Shares out
57,436,000
Stochastic %K
34%
Beta
-0.04
Analysts
Strong Sell
Price target
$27.87

Price

Company profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy...

Show more

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
866 857 2596
Website
https://climbbio.com
Address
20 William Street, Suite G50, Wellesley Hills, United States

Latest news

Stocktwits

ajmrtxl Oct 27, 4:41 PM
$CLYM 's latest squeeze play
0 replies
stockpicker63 Oct 27, 4:16 PM
$CLYM nice profit +7.5 in about 1.5hr
0 replies
ajmrtxl Oct 27, 4:03 PM
$CLYM 's latest squeeze play
0 replies
stockpicker63 Oct 27, 2:38 PM
🚨 $CLYM (Climb Bio) – Swing Trade Analysis Fundamentals: 6/10 | AI Score: 7.5/10 Trend: Reversing off $8.80 support 📈 Setup: LONG (1–5 Days) Entry: $9.00 – $9.25 Target: $9.85 (TP1) | $10.15 (TP2) Stop-Loss: $8.55 Risk: High (Biotech Catalyst Rebound)
0 replies
Quantumup Oct 27, 2:11 PM
Piper Sandler reiterated $CLYM Overweight-$40 and said that it Believes It's a Good Time to Own Ahead of Strong Catalyst-Flow after its Virtual Group Investor Meeting Post-ASN $VERA $TVTX JBIO RHHBY BIIB VRTX Here's what Piper Sandler said in its note: https://x.com/Quantumup1/status/2115083856348934469?s=20
0 replies
Merlintrader Oct 26, 9:01 PM
$CLYM presented first Phase 2 PrisMN data for budoprutug in primary membranous nephropathy (ASN oral presentation). Not investment advice. https://www.merlintrader.com/climb-bio-clym-stock-hub/
0 replies
mastersnafu Oct 26, 5:24 PM
$CLYM once again I am wrong! Like all these analysts with their price target!
1 replies
Quantumup Oct 26, 11:16 AM
Guggenheim reiterated $CLYM Buy-$35 after the Co. presented updates on budoprutug (budo; anti-CD19) in PMN and two healthy-volunteer (HV) datasets for CLYM116 (anti APRIL sweeper mAb) at ASN Kidney week 2026. $VERA $TVTX JBIO RHHBY BIIB VRTX Here's what Guggenheim said: https://x.com/Quantumup1/status/2114677434712822041?s=20
0 replies